<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28176222</PMID>
      <DateCompleted>
        <Year>2017</Year>
        <Month>05</Month>
        <Day>02</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1179-1950</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>77</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drugs</Title>
          <ISOAbbreviation>Drugs</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.</ArticleTitle>
        <Pagination>
          <StartPage>319</StartPage>
          <EndPage>330</EndPage>
          <MedlinePgn>319-330</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-017-0697-1</ELocationID>
        <Abstract>
          <AbstractText>Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern<sup>®</sup>) are indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus (T2DM), either when treatment with metformin and/or a sulfonylurea plus a monocomponent of saxagliptin/dapagliflozin provides inadequate glycaemic control, or when the patient is already being treated with the free combination of saxagliptin + dapagliflozin. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of saxagliptin/dapagliflozin in this indication. The agents have complementary mechanisms of action, and saxagliptin/dapagliflozin fixed-dose combination tablets are bioequivalent to free combination of saxagliptin + dapagliflozin. In three phase III trials, saxagliptin + dapagliflozin + metformin was more effective at providing glycaemic control than saxagliptin + metformin or dapagliflozin + metformin in previously treated patients with T2DM and inadequate glycaemic control on metformin monotherapy or metformin plus one of the monocomponents. The combination is associated with decreased bodyweight and a low risk of hypoglycaemia. As the first dipeptidyl peptidase-4 (DPP-4) inhibitor/sodium-glucose co-transporter (SGLT2) inhibitor fixed-dose combination available in the EU for glycaemic control in patients with T2DM, saxagliptin/dapagliflozin is a useful new option in this setting.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Garnock-Jones</LastName>
            <ForeName>Karly P</ForeName>
            <Initials>KP</Initials>
            <AffiliationInfo>
              <Affiliation>Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>New Zealand</Country>
        <MedlineTA>Drugs</MedlineTA>
        <NlmUniqueID>7600076</NlmUniqueID>
        <ISSNLinking>0012-6667</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005960">Glucosides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1ULL0QJ8UC</RegistryNumber>
          <NameOfSubstance UI="C529054">dapagliflozin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001559" MajorTopicYN="N">Benzhydryl Compounds</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2017</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28176222</ArticleId>
        <ArticleId IdType="doi">10.1007/s40265-017-0697-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s40265-017-0697-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>N Engl J Med. 2013 Oct 3;369(14):1317-26</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23992601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Br J Clin Pharmacol. 2013 Mar;75(3):763-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22823746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Ther. 2015 Sep;6(3):357-75</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26323372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2013 Apr;15(4):291-300</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23013323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2015 Mar;38(3):376-83</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25352655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 2014 Dec;74(18):2191-209</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25389049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Expert Opin Drug Metab Toxicol. 2016 Dec;12 (12 ):1407-1417</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27435042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2016 Nov;18(11):1128-1133</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2017 Feb;40(2):284-286</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27659407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BJU Int. 2016 Jul;118(1):16-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26469199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2015 Nov;38(11):2018-24</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26324329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eur Heart J. 2016 May 14;37(19):1526-34</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26819227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pharmacol Res Perspect. 2016 Jan 12;3(6):e00201</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27022473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2015 Nov;38(11):2009-17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26246458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clin Ther. 2016 Aug;38(8):1890-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27491280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Obes Metab. 2016 Nov;18(11):1134-1137</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27385192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 2015 Oct;75(15):1783-96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26403305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drugs. 2012 Jan 22;72(2):229-48</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22221000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetologia. 2015 Mar;58(3):429-42</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25583541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diabetes Care. 2015 Mar;38(3):373-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25715413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endocr Pract. 2014 Nov;20(11):1187-97</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25370334</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
